Incannex expands IHL-675A indications to include COPD, asthma, bronchitis, and other inflammatory lung conditions – after receiving positive results from additional in vivo studies Feb 4, 2021 ASX News Incannex Healthcare (ASX:IHL) Send Share Share
Incannex enters a lease for first psychedelic-assisted psychotherapy clinic May 5, 2023 | Incannex Healthcare (ASX:IHL)
Nyrada Quarterly Activities Report & Appendix 4C 30 Jun 2022 Jul 26, 2022 | ASX News, Nyrada Inc (ASX:NYR)
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis Feb 28, 2023 | ASX News, Incannex Healthcare (ASX:IHL)